Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients
Key facts
- Who runs it
- Istinye University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 80 people, planned
- Started
- 15 Jan 2026
- Planned end
- 31 May 2026
- Type of study
- Observational
- Treatments tested
- Non-interventional / Observational Study
- Record updated
- 13 January 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients aged 65 years and older
- Diagnosis of sepsis according to SEPSIS-3 criteria
- Admission to the intensive care unit
- No acute kidney injury at admission according to KDIGO classification
- Measurement of serum uric acid, albumin, and lactate levels at ICU admission
- SOFA score calculated at ICU admission
- ICU follow-up of at least 24 hours
Who cannot take part
- Uncompensated or decompensated chronic liver disease (e.g., Child-Pugh class C)
- Active malignancy or receipt of active cancer treatment within the last 6 months
- Chronic kidney disease stage 4 or 5 (eGFR <30 mL/min/1.73 m²)
- Missing or incomplete clinical/laboratory data
- Age under 65 years
- Presence of acute kidney injury at admission according to KDIGO criteria
- ICU follow-up less than 24 hours
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis.
Read full original descriptionShow less
This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included.
The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.
Treatments tested
- Non-interventional / Observational Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Predictive Value of the Combination of Uric Acid/Albumin Ratio and Lactate for Acute Kidney Injury, Hemodynamic Support Requirement, and Mortality in Patients With Sepsis
- Record updated
- 13 January 2026